Debate: Transplant vs. CAR T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

The advent of CAR T-cell therapy represents a major paradigm shift for management of patients with relapsed or refractory diffuse large B-cell lymphomas (DLBCL). The choice of treatment for relapsed or refractory DLBCL should be based on the response to second-line therapy, timing of relapse, eligibility to undergo transplant, access to CAR T-cell therapy and patient/physician preference. Educating clinicians about the recent clinical advances and the benefits/risks associated with the use of transplant and CAR T-cell therapy can help them to make informed clinical decisions for individual patients.

Target Audience

This educational program is designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, PAs, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this program, participants should be able to:

  • Summarize the evidence from clinical trials supporting the use of high-dose therapy followed by autologous hematopoietic cell transplant for patients with relapsed/refractory diffuse large B-cell lymphomas (DLBCL).
  • Review the safety and efficacy of currently approved CAR T-cell therapies and other targeted therapies for relapsed or refractory DLBCL.
  • Develop an individualized treatment plan for patients with relapsed/refractory DLBCL.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • GlaxoSmithKline
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Kite, A Gilead Company
  • Lilly
  • Novartis
  • Seagen
  • Taiho Oncology, Inc.

This activity is supported by independent educational grants from:

  • AbbVie
  • Bristol Myers Squibb
  • Daiichi Sankyo
  • Incyte
  • Merck & Co., Inc.

This program is supported by independent medical education grants from:

  • Jazz Pharmaceuticals
  • Pfizer Inc.

This activity is supported by educational funding provided by Amgen.

This activity is supported by a medical education grant from Karyopharm Therapeutics.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Course opens: 
12/15/2022
Course expires: 
12/15/2023
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2022 Annual Congress: Hematologic Malignancies™

Jeremy S. Abramson, MD, MMSc
Massachusetts General Hospital Cancer Center

Mazyar Shadman, MD, MPH
Fred Hutchinson Cancer Center

Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center

 

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions 

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Jeremy S. Abramson, MD, MMSc 
AstraZeneca Pharmaceuticals LP: Honoraria
BeiGene: Consulting Fee; Honoraria
bluebird bio, Inc.: Consulting Fee
Bristol-Myers Squibb Company: Consulting Fee; Grant/Research Support; Honoraria
Caribou Biosciences, Inc.: Consulting Fee
Eli Lilly and Company: Consulting Fee
Epizyme: Consulting Fee
Genentech, Inc.: Consulting Fee
Genmab A/S: Honoraria
Incyte Corporation: Honoraria
Janssen Pharmaceutica Products, LP: Consulting Fee
Kite Pharma: Consulting Fee
Kymera Therapeutics: Consulting Fee
MorphoSys AG: Consulting Fee
Mustang Bio: Consulting Fee
Ono Pharmaceutical Co., Ltd.: Consulting Fee
Regeneron Pharmaceuticals, Inc.: Honoraria
Seattle Genetics, Inc.: Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Consulting Fee

Mazyar Shadman, MD, MPH
AbbVie, Inc.: Consulting Fee; Grant/Research Support
Adaptimmune Therapeutics plc: Consulting Fee
Adaptive Biotechnologies: Consulting Fee
AstraZeneca Pharmaceuticals LP: Consulting Fee; Grant/Research Support
Atara Biotherapeutics: Consulting Fee; Grant/Research Support 
BeiGene: Consulting Fee; Grant/Research Support
Bristol-Myers Squibb Company: Consulting Fee; Grant/Research Support
Celgene Corporation: Grant/Research Support
Eli Lilly and Company: Consulting Fee
Epizyme: Consulting Fee
Genentech, Inc.: Consulting Fee; Grant/Research Support
Genmab A/S: Grant/Research Support
Gilead Sciences, Inc.: Grant/Research Support
Innate Pharma, Inc.: Consulting Fee
Kite Pharma: Consulting Fee
MEI Pharma Inc.: Consulting Fee
Merck & Co., Inc.: Consulting Fee
MorphoSys AG: Grant/Research Support
Mustang Bio: Consulting Fee; Grant/Research Support
Pharmacyclics: Consulting Fee; Grant/Research Support
Regeneron Pharmaceuticals, Inc.: Consulting Fee
Sound Biologics: Consulting Fee
Sunesis Pharmaceuticals, Inc.: Grant/Research Support 
TG Therapeutics, Inc.: Consulting Fee; Grant/Research Support
Vincerx Pharma: Grant/Research Support 

Andrew D. Zelenetz, MD, PhD (also a member of the Congress Planning Committee)
AbbVie, Inc.: Consulting Fee 
Adaptive Biotech: Consulting Fee
Amgen Inc.: Consulting Fee
AstraZeneca Pharmaceuticals LP: Consulting Fee
BeiGene: Consulting Fee; Grant/Research Support
BMS/Celgene/Juno: Consulting Fee; Scientific Advisor
Celgene Corporation: Consulting Fee
Genentech, Inc.: Consulting Fee; Grant/Research Support
Gilead Sciences, Inc./Kite Pharma: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee
MEI Pharma Inc.: Consulting Fee; Grant/Research Support
MorphoSys AG: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Roche Laboratories, Inc.: Consulting Fee; Grant/Research Support

Congress Planning Committee Disclosures

The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose. 

Brenda K. Shelton, DNP, RN, CCRN, AOCN, NPD-BC 

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated. 

Gabriela S. Hobbs, MD 
AbbVie, Inc.: Scientific Advisor
Agios, Inc.: Scientific Advisor
Bayer HealthCare: Grant/Research Support
Blueprint Medicines: Scientific Advisor
Bristol-Myers Squibb Company: Scientific Advisor
Celgene Corporation: Scientific Advisor
Incyte Corporation: Grant/Research Support; Scientific Advisor
Jazz Pharmaceuticals Inc.: Scientific Advisor
Merck & Co., Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Scientific Advisor 

Shaji K. Kumar, MD
AbbVie, Inc.: Grant/Research Support; Scientific Advisor
Amgen Inc.: Grant/Research Support; Scientific Advisor 
BeiGene: Honoraria
Bristol-Myers Squibb Company: Grant/Research Support; Scientific Advisor
GlaxoSmithKline: Grant/Research Support; Scientific Advisor
Janssen Pharmaceutica Products, LP: Grant/Research Support; Scientific Advisor
Karyopharm Therapeutics: Grant/Research Support; Scientific Advisor
Loxo Oncology, Inc.: Scientific Advisor
Regeneron Pharmaceuticals, Inc.: Grant/Research Support; Scientific Advisor
Roche Laboratories, Inc.: Grant/Research Support; Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support; Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support; Scientific Advisor

Bernard Marini, PharmD, BCOP
Servier Laboratories: Consulting Fee

NCCN Staff Disclosures 

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-22-125-H01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until December 15, 2023. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing